Jon Rees PhD

CEO, MitoRx Therapeutics. Pioneering therapeutics in mitochondrial-driven disease.

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we announced the enrollment of the first individual in a Phase 1 study evaluating ARQ-234, a potential biologic treatment for moderate to severe #AtopicDermatitis.

Learn more: https://t.co/Lb1NGElw4G

#ClinicalDermatology

[Jon Rees PhD @BiotechJon]

13 years later... today (25th August 2025), Organox acquired for $1.5b by Terumo for their normothermic organ transplant technology.

[Jon Rees PhD @BiotechJon]

That's the great thing about Oxbridge, saw the future of liver transplantation on my way to another meeting: OrganOx

[Jon Rees PhD @BiotechJon]

Impressive to see $ARQT +169% total prescriptions growth in Q1 2025 vs. Q1 2024, and doubling of Arcutis' revenues year-on-year.

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today, we announced #Q1 2025 financial results. Read our release for full details and business updates: https://t.co/tzOzRHQNM6

$ARQT

[Jon Rees PhD @BiotechJon]

Very interesting results in Regulus' #ADPKD oligo program (RGLS8429), an indication *larger* than Parkinson's Disease in patient numbers with about 12.5 million patients worldwide making it the most common monogenic disorder. They report halting cyst growth. #biotech #Regulus

[Jon Rees PhD @BiotechJon]

MitoRx Therapeutics is presenting at #BIOEurope Spring 2025 sharing the latest data demonstrating weight loss with muscle preservation

[Jon Rees PhD @BiotechJon]

Jefferies lifts Arcutis price target to $19 https://t.co/EnNA1U4lBC

[Jon Rees PhD @BiotechJon]

Mizuho's upgraded outlook for $ARQT takes the average one-year price target for Arcutis Biotherapeutics to $19.38, driving intraday gains above 7% https://t.co/wo8vj1mxZH

[Jon Rees PhD @BiotechJon]

Thanks to @LongevityTech for highlighting the promise of MitoRx Therapeutics' technology in metabolic disease this week.

[Longevity Technology @LongevityTech]

MitoRx demonstrates mitochondrial therapy holds potential in metabolic disease...
Study shows #mitochondria-targeted donor therapy reduces #weightgain and protects against #muscleloss in mice
@MitoRxTheraLtd @BiotechJon
#longevity #obesity #biotech #GLP1
https://t.co/AlcArQhUK6

[PKD Charity UK @PKDCharity]

📢Passionate about making a difference?

We're looking for a dedicated and motivated CEO to lead our national charity supporting PKD patients, carers, and renal clinicians.

Join us in our mission to improve lives. Find out more and apply:https://t.co/Qq0clfadOF

[MitoRx Therapeutics @MitoRxTheraLtd]

We’ve appointed 4 additional experts @oligogirl @HansbroResearch @CarolineGuiner @MilosFi37777561 to our SAB, to support developing treatments for degenerative diseases with the world's only mitochondrial platform restoring sulfide-signaling. @biotechjon

https://t.co/1CR9mQTUL0

[Jon Rees PhD @BiotechJon]

I was deeply saddened about the passing of Tess Harris, PKD Charity UK CEO. PKD is one of the most common genetic diseases affecting up to 70,000 people in UK, 600,000 in the US and 12 million worldwide, but remains grossly underserved by our industry. Let's change that.

[PKD Charity UK @PKDCharity]

💜With profound sorrow, we announce the passing of our beloved CEO, Tess Harris, peacefully on March 1, 2024.
A tireless advocate for PKD, her visionary leadership and dedication will forever inspire us.💜
Full statement: https://t.co/6Dr1km5nzP

[MitoRx Therapeutics @MitoRxTheraLtd]

@BiotechJon will share insights at #BIOEuropeSpring into our first-in-class mitochondriotropic therapeutics, now validated preclinically in mammalia. These restore sulfide-signalling, which can arrest progression in degenerative conditions.
🤝 Book a mtg: https://t.co/5iqY8f6OEq

[Jon Rees PhD @BiotechJon]

Looking forward to sharing positive preclinical results from MitoRx's programs modulating mitochondrial dysfunction to arrest decline in degenerative diseases at #JPM24 next week...

[MitoRx Therapeutics @MitoRxTheraLtd]

@Biotechjon is at #BiotechShowcase2024 on Jan 8-9, presenting our groundbreaking therapeutic pipeline targeting mitochondria dysfunction in rare diseases like #Duchenne & #Huntingtons. Hear about our promising preclinical results and recent financing news! https://t.co/V9Kld6jecy

[Jon Rees PhD @BiotechJon]

Preprint alert: Vignane shows oxidation of cysteine residues promotes aberrant LLPS and aggregation (seen in ND) and cysteine persulfidation prevents this. Protective persulfidation is impaired in neurodegeneration, MitoRx restores this. 1 minute summary:
https://t.co/LPA4reo963

[Glyn Edwards @edwards_glyn]

Really interesting paper validating @MitoRxTheraLtd technology. Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treated Caenorhabditis elegans | PNAS https://t.co/UufAmMeoe2

[Jon Rees PhD @BiotechJon]

Over 60% of FDA-approvals of new drugs from the top 20 pharma originate externally (including 6% from collaboration). And only 3% originate in Universities. Read that last bit again. Tell everyone you know this: biotech is the crucible for innovation.

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Investigating the origins of recent pharmaceutical innovation https://t.co/t1jeBlcDWL
An analysis of new drugs from the top 20 biopharma companies indicates that their business model in recent years has largely been built on external innovation, as only 28% originated internally

[HM Treasury @hmtreasury]

Silicon Valley Bank UK has today been sold to @HSBC.

This transaction has been facilitated by the @bankofengland in consultation with HM Treasury.

No taxpayer money is involved and customer deposits have been protected.

Find out more ⬇️

https://t.co/Dmfjdx7duC

[Jon Rees PhD @BiotechJon]

The Fed and Treasury have set the bar: backstoping all SVB US depositors. EB-5 green card option will look attractive if tomorrow the UK falls short on backstoping SVB UK depositors who underpin our knowledge economy @Jeremy_Hunt @hmtreasury @griffitha
https://t.co/aAUeR3cp4D

[Jon Rees PhD @BiotechJon]

Proud to lead the growing MitoRx team pioneering the development of a unique technology to tackle mitochondrial-driven disease.

[MitoRx Therapeutics @MitoRxTheraLtd]

We’re delighted to welcome Christine Charman as Chief Development Officer and David Richardson as Finance Director. We also have our new Scientific Advisory Board with Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.

[Jon Rees PhD @BiotechJon]

@MitoRxTheraLtd's new appointments covered in BioCentury

[BioCentury @BioCentury]

BioCentury's latest roundup of management moves: Catalano named CSO of Capsida. Plus: Wagner to head government affairs at ElevateBio and updates from Novo Nordisk, AuraVax, MitoRx and more $NOVO https://t.co/xtKBbAKTia